• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Tevogen Bio Holdings Inc.

    7/10/26 5:17:07 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TVGN alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the Securities and Exchange Commission on July 10, 2026

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

     

     

    Tevogen Bio Holdings Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   98-1597194

    (State or other jurisdiction

    of incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

         

    15 Independence Boulevard, Suite #210

    Warren, New Jersey 07059

      07059
    (Address of Principal Executive Offices)   (Zip Code)

     

    Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan

    (Full title of the plan)

     

    Ryan Saadi

    Chief Executive Officer

    Tevogen Bio Holdings Inc.

    15 Independence Boulevard, Suite #210

    Warren, New Jersey 07059

    (Name and address of agent for service)

     

    (877) 838-6436

    (Telephone number, including area code, of agent for service)

     

     

     

    Copies to:

    William I. Intner

    J. Nicholas Hoover

    Hogan Lovells Cadwalader US LLP

    100 International Drive, Suite 2000

    Baltimore, Maryland 21202

    (410) 659-2700

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

           
    Large accelerated filer ☐ Accelerated filer ☐
           
    Non-accelerated filer ☒ Smaller reporting company ☒
           
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    Tevogen Bio Holdings Inc. (the “Company”) is filing this registration statement with the Securities and Exchange Commission (the “SEC”) to register the sale and issuance of up to 2,201,037 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), authorized for issuance pursuant to awards under the Company’s 2024 Omnibus Incentive Plan (the “Plan”), pursuant to (1) the provisions of the Plan providing for an automatic increase in the number of shares of Common Stock available for issuance under the Plan on January 1, 2026 and (2) an amendment to the Plan to increase the number of shares of Common Stock available for issuance thereunder that was adopted by the Company’s Board of Directors on January 15, 2026 and approved by the Company’s stockholders at a special meeting held on February 19, 2026. The Company previously registered the sale of shares of Common Stock under the Plan on registration statements on Form S-8 filed with the SEC on June 10, 2024 and May 1, 2025 (File Nos. 333-280075 and 333-286890) (the “Prior Registration Statements”).

     

    On March 6, 2026, the Company effected a reverse stock split of its outstanding shares of Common Stock at a ratio of 1-for-50 (the “Reverse Stock Split”). The number of shares of Common Stock registered hereby gives effect to the Reverse Stock Split and the shares of Common Stock registered by the Prior Registration Statements have been automatically adjusted to give effect to the Reverse Stock Split.

     

    Pursuant to General Instruction E to Form S-8, this registration statement hereby incorporates by reference the contents of the Prior Registration Statements except as set forth below.

     

     

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    Exhibit    
    Number   Description
    4.1   Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on February 14, 2024 (File No. 001-41002))
         
    4.2   Certificate of Amendment to the Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on March 4, 2026 (File No. 001-41002))
         
    4.3   Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on April 25, 2025 (File No. 001-41002))
         
    5.1   Opinion of Hogan Lovells Cadwalader US LLP*
         
    23.1   Consent of KPMG LLP, independent registered public accounting firm*
         
    23.2   Consent of Hogan Lovells Cadwalader US LLP (included in Exhibit 5.1)*
         
    24.1   Power of Attorney (included on signature page)
         
    99.1   Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.8 filed with the Company’s Current Report on Form 8-K filed on February 14, 2024)
         

    99.2

      Amendment No.1 to Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 filed with the Company’s Current Report on Form 8-K filed with the SEC on February 25, 2026)
         
    99.3   Form of Restricted Stock Unit Agreement under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (incorporated by reference to Exhibit 99.2 to the Company’s Registration Statement on Form S-8 (File No. 333-280075) filed with the SEC on June 10, 2024)
         
    107   Filing Fee Table*

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Warren, State of New Jersey, on this 10th day of July, 2026.

     

    TEVOGEN BIO HOLDINGS INC.  
         
    By:

    /s/ Ryan Saadi

     
      Ryan Saadi  
      Chief Executive Officer and Chairperson of the Board of Directors  

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Ryan Saadi and Kirti Desai, and each of them, such person’s true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this registration statement, and any registration statement relating to the offering covered by this registration statement and filed pursuant to Rule 462(b) under the Securities Act of 1933, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or such person’s substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             

    /s/ Ryan Saadi

      Chief Executive Officer and Chairperson of the Board of Directors   July 10, 2026
    Ryan Saadi   (Principal Executive Officer)    
             

    /s/ Kirti Desai

      Chief Financial Officer   July 10, 2026
    Kirti Desai   (Principal Financial Officer and Principal Accounting Officer)    
             

    /s/ Jeffrey Feike

      Director   July 10, 2026
    Jeffrey Feike        
             

    /s/ Dr. Keow Lin Goh

      Director   July 10, 2026
    Dr. Keow Lin Goh        
             

    /s/ Dr. Curtis Patton

      Director   July 10, 2026
    Dr. Curtis Patton        
             

    /s/ Susan Podlogar

      Director   July 10, 2026
    Susan Podlogar        
             

    /s/ Victor Sordillo

      Director   July 10, 2026
    Victor Sordillo        

     

     

     

    Get the next $TVGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TVGN

    DatePrice TargetRatingAnalyst
    3/4/2026Buy → Hold
    D. Boral Capital
    3/4/2025$10.00Buy
    D. Boral Capital
    More analyst ratings

    $TVGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tevogen Bio Announces 2026 Annual Meeting of Stockholders

    WARREN, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) announced that its 2026 Annual Meeting of Stockholders (the "Annual Meeting)" is scheduled for Monday, August 24, 2026. The Annual Meeting will be held virtually. Stockholders of record as of July 23, 2026 will be entitled to receive notice of and vote at the Annual Meeting or any adjournment thereof. Because the meeting date is more than 30 days after the one-year anniversary date of the 2025 Annual Meeting, stockholder proposals submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934 (the "Exchange Act") for consideration at the Annual Meeting must be receive

    7/13/26 10:15:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Announces Formation of a Healthcare Services Initiative

    William Keane Appointed Interim Head of Initiative, Evaluating Potential Management Services Organization and Contract Research Organization Acquisitions WARREN, N.J., June 09, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced the formation of its healthcare services initiative, a strategic business area intended to support the Company's evolution into a broader, revenue-generating healthcare enterprise. The initiative will be led on an interim basis by William Keane, Tevogen's Vice President of Strategic Initiatives. The healthcare services initiative may include, if consummated, the Company's currently evaluated acquisition oppo

    6/9/26 3:30:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

    WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consummated, could realize approximately $100 million in combined annual revenue. These initiatives include the Company's previously announced evaluation of a contract research organization ("CRO"), along with additional strategic acquisition opportunities aligned with Tevogen's broader healthcare platform. Tevogen believes these and other strategic acquisition initiatives could support the Compan

    5/28/26 12:30:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Desai Kirti bought $2,460 worth of shares (3,000 units at $0.82), increasing direct ownership by 0.03% to 9,699,186 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    6/13/24 4:30:24 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Saadi Ryan H. bought $2,000 worth of shares (2,607 units at $0.77), increasing direct ownership by 0.00% to 118,252,659 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    6/7/24 4:29:51 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sordillo Victor J. was granted 40,000 shares, increasing direct ownership by 347% to 51,539 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    7/10/26 5:31:45 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Saadi Ryan H. was granted 1,220,000 shares, increasing direct ownership by 49% to 3,705,689 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    7/10/26 5:31:31 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Podlogar Susan M was granted 40,000 shares, increasing direct ownership by 461% to 48,678 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    7/10/26 5:31:18 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tevogen Bio downgraded by D. Boral Capital

    D. Boral Capital downgraded Tevogen Bio from Buy to Hold

    3/4/26 9:36:27 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    D. Boral Capital initiated coverage on Tevogen Bio with a new price target

    D. Boral Capital initiated coverage of Tevogen Bio with a rating of Buy and set a new price target of $10.00

    3/4/25 8:26:08 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    SEC Filings

    View All

    SEC Form S-8 filed by Tevogen Bio Holdings Inc.

    S-8 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

    7/10/26 5:17:07 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Tevogen Bio Holdings Inc.

    424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

    6/26/26 9:18:18 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Tevogen Bio Holdings Inc.

    EFFECT - Tevogen Bio Holdings Inc. (0001860871) (Filer)

    6/26/26 12:15:10 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    Leadership Updates

    Live Leadership Updates

    View All

    Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

    WARREN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today issued a statement from Founder and CEO Dr. Ryan Saadi regarding the company's progress in developing TVGN 489 for Long COVID, timed with International Long COVID Awareness Month. Following the appointment of a new leadership team on March 9, 2026, Tevogen is accelerating its "Biotech" and "Digital Health" verticals to move TVGN 489 into its next clinical phase. The company is currently evaluating the acquisition of Sciometrix and its Clinicus platform to provide real-world monitoring for Long COVID patients. Tevogen continues to prioritize the development of TVGN 489,

    3/11/26 3:15:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Names Leadership Team to Execute Diversified Growth Strategy

    WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced the appointment of interim leaders across its core business verticals to execute the first phase of its diversified growth strategy. In this first phase, Tevogen is evaluating strategic opportunities that, if completed, are expected to operate as subsidiaries of the Company and could collectively generate annual revenues exceeding $50 million. The Company expects these transactions to close by the second quarter of 2026, subject to customary due diligence and definitive agreements. Leadership Designations: Digital Health: Arpita Patel and Wojtek StobinskiGene

    3/9/26 7:45:00 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

    WARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced that Mittul Mehta, Chief Information Officer of Tevogen and Head of Tevogen.AI, will participate as a panelist in the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025. The Startup Forum will feature insights from venture capital leaders and early-stage innovators on how they are scaling their companies with Databricks. Mehta will join industry peers including Chris Gervais, CTO of Codametrix, and Stavros Papadopoulos, CEO of TileDB, in a discussion moderated by Tony Pezzullo, Principal at SignalFire. Mehta will share perspectives on Te

    9/10/25 11:59:02 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    Financials

    Live finance-specific insights

    View All

    Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

    Lead investor confirmed his intention to maintain his current shareholdings.Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next 12 months or until the company becomes cash-flow positive.Approximately only one-fifth of total shares outstanding are in the tradable float when accounting for Tevogen's lead investor, directors and named executive officers.Company prioritizing long-term stock-based incentive program aligned with company milestones.Board of Directors continues to evaluate the potential declaration of a one-time special cash dividend to shareholders.Company continues to evaluate acquisitions that could generate

    3/13/26 2:45:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

    WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent upon the achievement of specified financial milestones to be determined at a future date, which could include revenue and earnings targets. Any consideration of a special dividend would be subject to the Company's future financial performance, capital requirements, compliance with applicable solvency laws, including under the Delaware General Corporation Law, and final approval by the Board of Directors aft

    1/30/26 3:00:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

    Expenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024.Tevogen maximizes capital efficiency, maintains access to financing to support growth, and anticipates revenue by end of 2026; Exploring options to address limited tradable float.Building infrastructure, advancing AI, and expanding internal capabilities in a sector with limited growth. WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or the "Company) (NASDAQ:TVGN) announced its financial results for the fiscal quarter ended June 30, 2025, and filed its Form 10-Q with the Securities and Exchange Commission ("SEC

    8/19/25 12:10:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

    SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

    11/14/24 5:29:01 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

    SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

    11/12/24 4:28:55 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Tevogen Bio Holdings Inc.

    SC 13G - Tevogen Bio Holdings Inc. (0001860871) (Subject)

    3/4/24 4:24:14 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care